Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany
Standard
Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany. / Koehler, Johanna; Ritzer, Barbara; Weidlich, Simon; Gebhardt, Friedemann; Kirchhoff, Chlodwig; Gempt, Jens; Querbach, Christiane; Hoffmann, Dieter; Haller, Bernhard; Schmid, Roland M; Schneider, Jochen; Spinner, Christoph D; Iakoubov, Roman.
in: INFECTION, Jahrgang 49, Nr. 6, 12.2021, S. 1313-1318.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Kurzpublikation › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany
AU - Koehler, Johanna
AU - Ritzer, Barbara
AU - Weidlich, Simon
AU - Gebhardt, Friedemann
AU - Kirchhoff, Chlodwig
AU - Gempt, Jens
AU - Querbach, Christiane
AU - Hoffmann, Dieter
AU - Haller, Bernhard
AU - Schmid, Roland M
AU - Schneider, Jochen
AU - Spinner, Christoph D
AU - Iakoubov, Roman
N1 - © 2021. The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.
AB - Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.
KW - Antibodies, Monoclonal/therapeutic use
KW - COVID-19
KW - Cross Infection/drug therapy
KW - Cross-Sectional Studies
KW - Germany
KW - Humans
KW - Retrospective Studies
KW - SARS-CoV-2
KW - Tertiary Care Centers
U2 - 10.1007/s15010-021-01657-y
DO - 10.1007/s15010-021-01657-y
M3 - Short publication
C2 - 34244967
VL - 49
SP - 1313
EP - 1318
JO - INFECTION
JF - INFECTION
SN - 0300-8126
IS - 6
ER -